CN1199584C - Healthy food for balancing blood pressure and regulating blood fat and preparing method thereof - Google Patents
Healthy food for balancing blood pressure and regulating blood fat and preparing method thereof Download PDFInfo
- Publication number
- CN1199584C CN1199584C CNB02125883XA CN02125883A CN1199584C CN 1199584 C CN1199584 C CN 1199584C CN B02125883X A CNB02125883X A CN B02125883XA CN 02125883 A CN02125883 A CN 02125883A CN 1199584 C CN1199584 C CN 1199584C
- Authority
- CN
- China
- Prior art keywords
- health food
- blood pressure
- food
- blood
- filtrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The present invention relates to a novel health food for blood pressure balance and blood fat regulation, and a preparation technique thereof. The present invention takes loranthus parasiticus, black soybean and jujube as raw materials which are pure natural plants with medicine-food function. The food is prepared by material selection, impregnation, water extraction, filtration, clarification, concentration, separation, micro-filtration and potting. The present invention has the characteristics of a simple but effective formula which comprises three medicines, rational compatibility, a rigorous design, a scientific preparation process, the advanced technique, low cost, an accurate dose, convenient administration, security and stability in use, good and conspicuous effect and sweet and good taste; therefore, the present invention is an ideal pure natural health food for middle-aged and old-aged people to balance blood pressure, regulate blood fat, reduce blood viscosity, improve microcirculation, prevent cerebrovascular diseases, delay aging and extend lifetime.
Description
Technical field
The present invention relates to a kind of balancing blood pressure, regulate the health functional food of blood fat, be the health food of basic material specifically, the invention still further relates to the preparation method of this health functional food through the preparation of modern times extraction science and technology with pure natural medicine-food two-purpose food plant.
Background technology
Hypertension is modal a kind of chronic difficult disease of coagulating, it also is popular utmost point angiocardiopathy widely in the world today, without good control, can cause a series of pathologies such as coronary heart disease, heart failure, cerebral apoplexy, renal damage for a long time, gently then causing the work forfeiture, can't take care of oneself, heavy then cause death, human health is threatened greatly, because how asymptomatic most of hypertensive patients are in early days, quiet, so be called " noiseless killer " visually by world medical circle.According to the WHO investigation result, the adult makes a definite diagnosis the hypertension illness rate about 8%-18%; In U.S. adult hypertension illness rate is 17.5%; Japan is 17%-22%; According to the 1986-1996 sample census, the hypertension illness rate is made a definite diagnosis by China more than 20 years old be 11%, in prediction on such basis, China hyperpietic reaches about 1.4 hundred million, and have and increase trend year by year, hypertension not only makes evidence of coronary heart diseases be multiplied, and is the major reason that causes cerebrovas-cularaccident and cardiorenal function infringement.
Hypertension was to remain the maximum single factors that formation early extremely disables today yesterday.Today, improve clinical efficacy and present bottleneck: 1, adult 11% suffers from hypertension among the crowd, and wherein 2/3 is light property or asymptomatic person, all need take medicine throughout one's life.Is 2, the difficulty of long-term treatment that the benefit/danger (expense) of medicine is such as what? whether quality of life impaired? 3, depressor is used the generation that can not reduce coronary heart disease.Though 4 medicines alleviate daily life myocardial anoxia ischemic patient's symptom, can not affirm whether reduce the death rate and miocardial infarction rate.5, still proof is not after left ventricular hypertrophy recovers, and Incidence of CHD and fatal rate reduce.6, exist anergy or Low Response and the toxicity of 20%-60% to medicine.
Modern Western medicine all is clearly monomer chemical analysis of structure, physicochemical property, though drug effect and action principle thereof are clear, but act on single relatively, further heighten the effect of a treatment, further potent as above-mentioned reason presents bottleneck, and heightening the effect of a treatment often is escalated dose, and the formation drug resistance is a cost, analyze from philosophy, this drug effect is single runs counter to multifactor, too many levels pathogenesis disease.Opposite with it, medicine-food two-purpose pure natural plant composition formula is won and one is raised, and the etiology and pathology multifactor, too many levels of the side's that coexists multiple effective ingredient and multiaspect preventive and therapeutic effect and disease matches, and just brings into play the good relatively curative effect of prophylactic treatment.Desirable medicine should be effectively, safety and stability, controlledly nontoxicly inexpensively take easyly, and can reverse fully and the blood pressure relevant cardiovascular and cerebrovascular disease that raises.
Summary of the invention
The object of the present invention is to provide a kind of balancing blood pressure, regulate blood fat, protect and be preced with the anti-blood viscosity of quivering, reduce, improve microcirculation, strengthen bone density, protect the liver, antifatigue, enhancing immunity, the no side reaction of safety, with low cost, it is sweet good to eat to distinguish the flavor of, the prevention cardiovascular and cerebrovascular disease, the desirable health food of anti-ageing life-prolonging.
Solution of the present invention is based on Chinese and western medical science to the clinical research in surplus hypertensive pathogenetic understanding and the author 30 year, abide by " sincerely examine the negative and positive place and transfer it; schedule to last " selected medicine-food two-purpose pure natural food plant, extract the refining pure natural health-care that forms of effective ingredient through the modern medicines extractive technique with flat.
Another object of the present invention provides preparation technology's method of this health functional food.
Pure natural medicine-food two-purpose health food of the present invention is made (consumption is a weight portion) by following prescription
18～29 parts of 46～68 portions of red dates of 18～36 portions of black soybean of parasitic loranthus
The prescription preferred weight ratio range for preparing pure natural medicine-food two-purpose health food of the present invention is
18～22 parts of 48～56 portions of red dates of 26～32 portions of black soybean of parasitic loranthus
The optimum weight proportioning of pure natural medicine-food two-purpose health food of the present invention is
18 parts of 51 portions of red dates of 29 portions of black soybean of parasitic loranthus
Above-mentioned each component is made pure natural medicine-food two-purpose production method of health food-Yizhibao of the present invention is:
1, selects materials and assort screening totally by the prescription weighing of will add medicine to.
2, water extraction parasitic loranthus, black soybean, red date 3 flavors add 8 times, 6 times, 6 times 100 ℃ of distilled water, and the 1st dipping 1h decocts 3 times, each 1h, and filtrate merges 3 filtrates successively, filters.
3, concentrate and to get filtrate and be evaporated to crude drug concentration 1.6g/ml.
4, separate and to get concentrate and successively add the ZTC/III natural clarifying agent 2A6B component for preparing, fully stir, 60 ℃～80 ℃ insulation 60min use tube centrifuge with 16000r/min centrifugation clear liquid, adjust soup crude drug concentration 1.8g/ml then.
5, micro-filtration is got supernatant and is added 1% Sodium Benzoate and fully dissolve.
6, embedding is got dosing after the dissolving by 0.15 μ m aperture mesopore fiber device micro-filtration, the aseptic embedding of filtrate.
Pure natural medicine-food two-purpose health food of the present invention shows to have following excellent characteristics through Clinical results for many years:
1, to select natural food plant for use be raw material to pure natural medicine-food two-purpose health food of the present invention, and each component meets the pharmaceutical control and administration state food, and the health hygienic law regulation is utilized effective ingredient combination comprehensive function prevention cardiovascular and cerebrovascular disease in the raw material, and it is anti-ageing to lengthen the life.
2, but health food of the present invention is taken balancing blood pressure for a long time and is regulated blood fat and reduce blood viscosity and improve microcirculation, the protection internal organs, and the prevention cardiovascular and cerebrovascular disease is eliminated clinical symptoms.
3, health food safety non-toxic of the present invention side reaction, better tolerance.
4, the cheap taking convenience of health food of the present invention
5, health food of the present invention all has tangible prevention and health care effect to hypertension, hyperlipidemia, artery sclerosis, coronary heart disease, osteoporosis.
Superior characteristics of the oral liquid of pure natural food plant of the present invention preparation are to contain flavone compound in the oral liquid; wherein contain Quercetin, poultry glucoside, mysoinositol, oleanolic acid isoreactivity effective ingredient; that the pharmacology extensive use has is hypotensive, reducing blood lipid, anti-oxidant, antiplatelet focuses on, the coronary artery dilating blood vessel; diuresis, efficacy effects such as protection gastrointestinal mucosa.
Another superior characteristics of the oral liquid of pure natural food plant of the present invention preparation are to contain a large amount of abundant nutritions in the oral liquid, wherein the unsaturated fatty acid fat contains 68.6%, protein 10.6%, it is that the aliphatic acid of needed by human plays the reduction blood fat in human body, reduce pernicious cholesterol and stop cholesterol in blood vessel, to deposit, prevent artery sclerosis, also has the stronger effect of bringing high blood pressure down, especially valuable hypertensive patient blood pressure after using reduce to normal after again the continuous application blood pressure no longer descend, reduce blood viscosity, effects such as antithrombotic.
Another superior characteristics of the oral liquid of pure natural of the present invention food plant preparation are to contain effectively nutrition such as 17 seed amino acids and a large amount of vitamin, inorganic matter, isoflavones, saponin, vitamin in the oral liquid, can promote gastric emptying effectively, the cleaning blood vessel, concora crush transfers fat to prevent cardiovascular and cerebrovascular disease, multiple diseases such as tumour, diabetes, osteoporosis, and safety, no side reaction, it is sweet good to eat to distinguish the flavor of, and is the optimal health food of mid-aged population.
The specific embodiment
Embodiment
Take by weighing raw material by following amount
Parasitic loranthus 360g black soybean 568g red date 260g
Production method is as follows:
Get parasitic loranthus, black soybean, red date 3 flavors add 8 times, 6 times, 6 times of 100 ℃ of boiling water or distilled water, soak 60min the 1st time, filtrate successively, merging 3 filtrates filters, it is 1.6g/ml that filtrate is concentrated into crude drug concentration, successively add ZTC-III natural clarifying agent 2A and the 6B component for preparing, fully stir, 60～80 ℃, insulation 60min uses tube centrifuge with 16000V/min centrifugation clear liquid, adjust soup then and be concentrated into the Sodium Benzoate that crude drug concentration is 1.8g/ml adding 1%, fully after the dissolving, by 0.15 μ m aperture mesopore fiber device micro-filtration, the aseptic subpackaged embedding of filtrate.
For showing that health food of the present invention is to hypertensive health-care efficacy, use this health food prophylactic treatment high blood pressure 30 examples in a year phase in December in January, 1996 to 2000, and establish Western medicine for contrasting, random packet is carried out the validity and the security of this health food of objective evaluation, and carry out zoopery, inquire into its mechanism.
1, zoopery result
A, hypotensive activity
Acute step-down experiment shows: health food of the present invention can claim balance and reduce ANR, CNR, 2KIC-RHR significantly greater than pressure value, in 30min appearance effect, heart rate obviously slows down in the time of the 2n effect of peaking continuing 4n～6n step-down, and obviously reduce the cardiac muscular tension time index, and the cardiac muscular tension time index is a yardstick weighing MCO, explanation is in step-down, and MCO reduces, and this cardiac load to the alleviating hypertension patient has certain benefit.Chronic step-down experiment shows; 20%, 10%, 5% dosage group to long-term 18 administrations of CNR rat after, its blood pressure, heart rate, cardiac muscular tension time index all obviously reduce, can make its hypertension recover normal behind the 5-10d, prove that health food of the present invention is in step-down and can also the reversing left ventricular hypertrophy, remove free radical, the arrhythmia of prevention ischemic, improve coronary blood flow, reduce in the glomerulus and press, reduce the equilibrium of supply and demand that albuminuria helps regulating and keeping myocardium oxygen metabolism and energy.
B, adjusting blood fat
Health food of the present invention can obviously reduce total cholesterol level in the hyperlipidemia rats blood, triglycerides, low-density lipoprotein, and its HDL can raise, prove that health food of the present invention has the bidirectional modulation blood fat, help eliminating the damage of oxygen radical, reduce arteriosclerotic incidence blood vessel.
C, improve hemorheological influence
Health food of the present invention can significantly reduce rat blood specific viscosity, whole blood contrast viscosity, packed cell volume; erythrocyte sedimentation rate and fibrinogen concentration; improve the dense sticking condensation degree of blood, reduce outer vascular resistence admittedly, improve microcirculation; adjust myocardial compliance; help eliminating the haemodynamics factor of left ventricular hypertrophy, the nitric oxide concentration that can raise reduces level of ET; reduce intracellular calcium concentration, the protection cardiorenal function.
2, animal toxicity test
A, acute toxicity test: 30 of mouse, each group are only given health-care food oral liquid 82mL/kg of the present invention (be equivalent to grow up day for human beings clothes dosage 1156 times), irritate stomach 1 time for every mouthful, all animals is movable normal after observing the 7d administration, appetite strengthens, and the stool and urine no abnormality seen does not also have the phenomena of mortality.
B, long term toxicity test
160 of rats, be divided into 4 groups at random, give physiological saline and health-care food oral liquid 40mL/kg of the present invention respectively, 20mL/kg, the every d of three dosage groups of 5mL/kg irritates stomach 1 time, continuously 90d, in putting to death animal behind the 24n after the last administration, broken end is got blood, surveys liver, renal function and Hb, RBC, WBC and classification respectively, dissects each internal organs.The result is during giving, and toxic reaction is not normally seen in the behavior of rat outward appearance, and diet, ight soil fur are normal, and it is good to grow, and each is organized rat body weight and all rises appreciably, indifference between group, and every liver, renal function and routine blood test are all within normal range (NR); Pathological section, each organizes important organs such as the rat heart, liver, lung, kidney, brain, and the tissue morphology structure does not all have obvious change.
3, clinical research result
3.1 diagnostic criteria: the diagnosis of formulating with reference to the hypertensive diagnostic criteria of WHO and national cardiovascular epidemic research in 1979 and crowd prevention and treatment forum is standard by stages, and the differential diagnosis in tcm standard is by " new Chinese medicine treatment high blood pressure clinical research guideline "
3.2 standard of including in: allly meet two doctor's diagnostic criteria, and meet differential diagnosis in tcm " deficiency of liver-yin and kidney-yin, phlegm stagnation in collateral " card.
3.3 exclusion standard: secondary hypertension, liver, renal insufficiency, the patient with phychlogical problems, all standards of including in that do not meet are not obeyed oral liquid in accordance with regulations, can't judge that curative effect or data are not congruent to affect the treatment or safe judgement person.
3.4 physical data: select altogether to observe case 60 examples, be divided into A group (oral liquid) 30 examples at random, B organizes (control group) 30 examples.A organizes 30 examples, wherein male 21 examples, and women 9 examples, 52.1 ± 6.8 years old mean age, the course of disease 7.9 ± 1.1 years merges coronary heart disease 12 examples, hyperlipidemia 23 examples, diabetes 2 examples, artery sclerosis 11 examples; Average 179.6 ± the 9.1mmHg of systolic pressure (SBP), the average 106.2 ± 9.2mmHg of diastolic pressure (DBP), 92.1 ± 15.6 times/min of heart rate (HR), I phase 3 examples, II phases 27 example, B organizes 30 examples, wherein male 19 examples, woman's 11 examples, 53.2 ± 6.9 years old mean age, the course of disease 7.7 ± 1.1 years, merge coronary heart disease 6 examples, hyperlipidemia 18 examples, diabetes 2 examples, artery sclerosis 8 examples; Systolic pressure (SBP) 176.2 ± 8.gmmHg, diastolic pressure (DBP) 1056. ± 9.0mmHg, 91.6 ± 13.2 times/min of heart rate, I phases 6 example, II phases 24 example.Analyze by statistics, the sex of two groups of cases, age course of disease accompanying symptoms and there are no significant by stages difference (P＞0.05) but the tool comparativity.
3.5 observation item index
3.5.1 electrocardiogram (ECG), systolic pressure (SBP), diastolic pressure (DBP), heart rate (HR) detects and record by " diagnostics " introduction method.
3.5.2 tcm symptom, adopt the method for sxemiquantitative symptom classification score to carry out observed and recorded with reference to " new Chinese medicine treatment high blood pressure clinical guidance principle ", every symptom is pressed " nothing " (-), " gently " (+), " in " (++), " weight " (+++) divide 4 grades, each (+) note 1 minute, (-) remembers 0 fen.
3.5.3 heart function: use XJS-HB type cardiac function automatic tester and detect, comprising: heartbeat output (SV), cardiac output (CO), heartbeat index (ST), cardiac index (CT), peripheral resistance (RT) and arterial compliance (AG) etc.
3.5.4 blood fat: the semi-automatic spectroanalysis instrument of French S.500P type is used in reference " new Chinese medicine treatment hyperlipemia disease clinical research guideline " and the living supporting medicine box in Beijing Chemical Plant detects, comprise: T-CHOL (TO), use the ferric trichloride development process; Triglycerides (TG) is used the acetylacetone,2,4-pentanedione development process; HDL (HDL) is with phosphorus, magnesium tungstate solwution method; Low-density lipoprotein (LDL) is obtained by the calculating of Friedwoid formula.
3.5.5 blood sugar: inspection apparatus is the same, measures with adjacent benzene methanamine method.
3.5.6 Hemorheology: get venous blood 4ml anticoagulant heparin on an empty stomach early morning, under 25 ℃ ± 0.5 ℃ constant temperature, use special equipments such as ELD type blood viscometer, the method for introducing with reference to " clinical hemorrheology " detects, comprise: WBV (RBV), plasma viscosity (RPV); With wintrobeShi determination of tube method packed cell volume (HCT), adopt wynn's method to detect erythrocyte sedimentation rate, and calculate ESR equation (K) in addition, measure plasma fibrinogen (Fb) with two vena contracta methods.
In addition, in order to observe the side reaction of oral liquid of the present invention, to detecting blood urine routine, hepatic and renal function before and after the treatment patient respectively, observation has or not any bad reaction during the clothes oral liquid.
3.6 GP TH method
Adopt parallel at random grouping, double blinding dual analog contrast method, according to table of random number the patient is divided into A group and B group successively, A organizes (invention oral liquid) 1 20mL, adds the outward appearance placebo consistent with B group FUFANG LUOBUMA PIAN 1 time 3,2 times on the 1st for 2 times on the 1st simultaneously, B group (FUFANG LUOBUMA PIAN) 1 time 3,2 times on the 1st adds 2 times on the 1st, 1 time 20ml of the outward appearance placebo consistent with the invention oral liquid simultaneously.
3.7 the course of treatment: 30d was 1 course of treatment.
3.8 the statistics word is managed outward: measurement data is checked with t, relatively adopts self paired t-test after the medication, relatively adopts the t check of two sample means between group, enumeration data X
2Check, curative effect is analyzed with Ridit, and all data all adopt the SPSS8.0 software analysis.
3.9 efficacy assessment standard
With reference to efficacy assessment standard in " the existing clinical research guideline of new Chinese medicine treatment hypertension " and " the practical clinical practice ".
3.9.1 blood pressure efficacy assessment standard
Produce effects: (1) diastolic pressure (DBP) decline 〉=1.3Kpa (10mmHg), and reach normal range (NR); (2) though diastolic pressure do not reduce to normally, to descend 〉=2.6Kpa (20mmHg).
Effectively: (1) has reached normal range (NR) though diastolic pressure does not descend≤1.3Kpa; (2) diastolic pressure is treated the preceding 1.3～2.34Kpa (10mmHg-19mmHg) of decline but is not reached normal range (NR); (3) shrink (SBP) preceding decline 〉=4Kpa (30mmHg) of treatment.
Invalid: as not reach above-mentioned standard.
3.9.2 tcm symptom efficacy assessment standard
By " new Chinese medicine treatment high blood pressure clinical guidance principle " six doing well,improving situations of the deficiency of liver-yin and kidney-yin is observation index: after all treatments before the treatment score reduce more than 2 minutes, or symptom alleviates disappearance person fully and is produce effects; Reduce more than 1 minute and sx disappearance person is effective; It is invalid reducing less than 1 minute and not disappearance of symptom person.
3.9.3 blood fat efficacy assessment standard
Work out " new Chinese medicine clinical research guideline " formulation blood fat curative effect judging standard according to the Ministry of Public Health in 1993 and reach following any one person, produce effects: TC descends 〉=20%; TG descends 〉=40%; LDL-CH descends 〉=20%; HDL-CH rising 〉=0.26mmoiL
-1Effective TC decline 10%-20%; TG decline 20%-40%; LDL-CH decline 10%-20%, the HDL-CH 0.10～0.26mmoiL that rises
-1Invalid; Do not reach effective standard.
3.10 treatment results
3.10.1 total effective rate relatively: A organizes 30 examples, produce effects 11 examples, effective 17 examples, invalid 2 examples, total effective rate 93.3%; B organizes 30 examples, produce effects 6 examples, and effective 13 examples, invalid 11 examples, total effective rate relatively has significant difference (X for 63.3%, two group
2=7.954 P＜0.01)
3.10.2 the blood pressure curative effect is relatively: SBP before and after the treatment between two groups, DBP HR changes relatively, sees Table 3, and comparing difference has conspicuousness (P＜0.01) before and after all other index treatments except that B group HR, and two groups of pressure values are controlled relatively there was no significant difference (P＞0.05) of back.
3.10.3 the tcm symptom curative effect relatively sees Table 4 treatment back A group patient 6 class symptoms different alleviating arranged all, its symptom total mark value reduces 49.4%, and except that 1 of pulse condition, the program that all the other 5 symptom integrations and total mark value reduce all is significantly higher than the B group.
3.10.4 relatively seeing Table 5 A groups (invention oral liquid), blood fat, blood sugar curative effect can obviously reduce the Serum of Patients with Hypertension T-CHOL, triglycerides and low-density lipoprotein, its HDL also can raise, have the blood sugar effect and the B group (control group) that reduce the patient simultaneously and compare, every index detects difference and all significantly is better than the B group.
3.10.5 the heart function curative effect relatively sees Table 6 treatment back A group heartbeat outputs, cardiac output, all obviously work risings of heartbeat exponential sum arterial compliance, and peripheral resistance obviously reduces, with all significantly preferential B group of the more every index of B group.
3.10.6 the Hemorheology curative effect relatively, the preceding two groups of blood of table 7 prompting treatment swash the every measured value of rheology and all are higher than normally, and treatment back 6 indexs of A group all obviously reduce, and difference all obviously is better than the B group.
3.10.7 side reaction, patient's routine blood test, routine urinalysis, liver, renal function detection all normally do not have significant change (all P＞0.05) clinical observation and also do not have bad phenomenon before and after application A group invention oral liquid.
Prove that from above-mentioned clinical research result the oral liquid of pure natural food plant society of the present invention preparation contains flavonoids, unrighted acid, osajin, effective ingredients such as interior phenmethylol glucoside and each seed amino acid, vitamin; Have stronger activity, have the health-care efficacy of remarkable nourishing kidney to calm liver invigorating the spleen, activating blood circulation to eliminate turbid vein relaxing, the mechanism that brings high blood pressure down is the result of the many-sided comprehensive function of health food of the present invention.1. increase the rich output of heart, cardiac output, improve heartbeat exponential sum main artery compliance, reduce peripheral resistance, prompting increases the heart pump function under the situation that does not increase heart rate and MCO, ground adds CF, help alleviating the patient's heart load, help regulating and keeping the equilibrium of supply and demand of myocardium oxygen metabolism and energy, eliminate risk factor.2. reduce patient's serum total cholesterol, triglycerides and low-density lipoprotein, its HDL that raises reduces blood-sugar content simultaneously, thereby prevents lipid in the deposition on arterial wall and erythrocyte membrane, and what interruption artery hardened develops.3. reduce patient's WBV; plasma viscosity; packed cell volume; reduce the content of plasma fibrinogen; thereby improve blood samples of patients " dense; sticking; as to coagulate; poly-" condition improvement microcirculation; protection heart kidney reaches balancing blood pressure; regulate blood fat; improve hemorheological property; reduce peripheral resistance, the protection heart and brain effectively prevent treatment hypertension; hyperlipidemia; coronary heart disease; artery sclerosis is useful; and safety and stability is with low cost, can take for a long time, shows that the refining oral liquid of pure natural medicine-food two-purpose food plant of the present invention is the sweet good to eat health functional food of flavor of mid-aged population indispensability.
Each amino acid composition content in table 1 oral liquid of the present invention
| Title | Content mg/100mL | Title | Content mg/100m | Title | Content mg/100m |
| Lysine | 1214.2 | Arginine | 963.6 | Proline | 686.6 |
| Methionine | 406.8 | Histidine | 206.4 | ||
| Tryptophan | 238.6 | Asparatate | 395.6 | ||
| Threonine | 406.8 | Serine | 548.6 | ||
| Isoleucine | 518.6 | Glutamic acid | 1559.2 | ||
| Leucine | 1117.0 | Tyrosine | 1068.2 | ||
| Phenylalanine | 1106.2 | Glycine | 889.2 | ||
| Valine | 402.3 | Alanine | 579.9 |
Each chemical element content in table 2 oral liquid of the present invention
| Title | Content mg/100mL | Title | Content mg/100m | Title | Content mg/100m |
| Potassium | 946.2 | Sulphur | 360.6 | Zinc | 289.6 |
| Sodium | 628.1 | Chlorine | 12.62 | ||
| Calcium | 1478.6 | Iron | 1068.8 | ||
| Magnesium | 1516.6 | Copper | 226.2 | ||
| Phosphorus | 128.6 | Manganese | 178.6 |
The flat oral liquid for relaxation of table 3 is to the influence of hyperpietic's blood pressure heart rate
| Project | Flat oral liquid for relaxation group (n=30) | Herba Apocyni veneti (Folium Apocyni Veneti) Tabellae group (n=30) | ||||
| Before controlling | After controlling | Difference | Before controlling | After controlling | Difference | |
| SBP (mmHg) DBP (mmHg) HR (inferior/min) | 179.6±9.1 106.2±9.2 92.1±15.6 | 179.6±9.1** 106.2±9.2** 92.1±15.6** | 30.5±1.5△△ 13.6±1.4△ 18.1±7.15△ | 176.2±8.9 105.6±9.0 91.6±13.2 | 156.0±4.3* 93.4±5.4* 76.4±5.0 | 20.2±4.6 12.2±3.6 15.2±8.2 |
Annotate: each group treatment front and back is * P＜0.05**P＜0.01 relatively
Two groups of differences compare P △＜0.05 △ △ P＜0.01
The flat oral liquid for relaxation of table 4 is to improve (X ± S equivalance integration) of high blood pressure tcm symptom
| Project | Flat oral liquid for relaxation group (n=30) | Herba Apocyni veneti (Folium Apocyni Veneti) Tabellae group (n=30) | ||||
| Before controlling | After controlling | Difference | Before controlling | After controlling | Difference | |
| The dizzy dizzy tinnitus palpitaition of having a headache soreness and weakness of waist and knees tongue picture uncomfortable in chest pulse condition total mark value | 2.93±0.771 2.25±0.73 1.98±0.88 2.11±0.94 1.86±0.92 1.79±0.82 12.92±3.85 | 1.41±0.42** 1.06±0.38** 0.58±0.24** 0.95±0.66** 1.09±0.87** 1.45±0.58** 6.54±2.02** | 1.52±0.59△ 1.19±0.57△ 1.40±0.57△△ 1.16±0.78△△ 0.77±0.52△△ 0.34±0.26 6.38±1.38△ | 3.04±0.91 2.18±0.54 1.83±0.84 2.01±0.89 1.94±0.89 1.86±0.92 12.86±3.91 | 1.79±0.72 1.22±0.52 1.57±0.77 1.58±0.67 1.52±0.72 1.49±0.68 9.17±2.84 | 1.25±0.49 0.96±0.36 0.26±0.21 0.43±0.48 0.42±0.31 0.37±0.29 3.69±1.63 |
Annotate: each group treatment front and back is * P＜0.05**P＜0.01 relatively
Two groups of differences compare P △＜0.05 △ △ P＜0.01
The flat oral liquid for relaxation of table 5 is to the influence of patients with hypertension blood-fat and blood sugar level (X ± Smm0l/L)
| Project | Flat oral liquid for relaxation group (n=30) | Herba Apocyni veneti (Folium Apocyni Veneti) Tabellae group (n=30) | ||||
| Before controlling | After controlling | Difference | Before controlling | After controlling | Difference | |
| TC TG HDL LDL BS | 6.06±1.12 2.64±0.57 1.18±0.38 3.41±0.73 5.29±1.22 | 4.41±0.97* 1.78±0.47* 1.46±0.59* 3.07±0.54* 4.41±0.92** | 2.65±0.28△ 0.86±0.20△ 0.28±0.12 0.34±0.16△△ 0.88±0.29△△ | 5.97±1.06 2.58±0.52 1.24±0.39 3.21±0.68 5.32±1.31 | 4.48±0.92* 1.18±0.48 1.42±0.44 3.01±0.51 5.18±1.26 | 1.49±0.25 0.18±0.12 0.18±0.10 0.20±0.11 0.14±0.10 |
Annotate: each group treatment front and back is * P＜0.05**P＜0.01 relatively
Two groups of differences compare P △＜0.05 △ △ P＜0.01
The flat oral liquid for relaxation of table 6 is to the influence of patients with hypertension cardiac functional parameter (X ± S)
| Project | Flat oral liquid for relaxation group (n=30) | Herba Apocyni veneti (Folium Apocyni Veneti) Tabellae group (n=30) | ||||
| Before controlling | After controlling | Difference | Before controlling | After controlling | Difference | |
| SV(ml/b) CO(l/min) SO(ml/m 2) CI(l/min..m 2) RT(mmhg..s/ml) AC(ml/mmhg) | 57.16±10.38 4.21±0.76 39.53±14.02 2.91±0.95 2.10±0.71 1.26±0.49 | 65.95±10.41** 4.91±0.82** 46.59±12.48* 3.36±0.99 1.71±0.52** 1.68±0.61** | 8.79±2.10△ 0.70±0.28△ 7.06±2.63△△ 0.45±0.11△ 0.39±0.10△ 0.42±0.14△△ | 56.70±12.42 4.91±0.91 36.97*±10.41 2.70±0.88 2.19±0.81 1.29±0.50 | 64.49.±12.81* 4.76±0.94* 41.47±12.55 3.10±0.96 1.85±0.74 1.55±0.59* | 7.79±1.98 0.57±0.25 4.50±1.48 0.40±0.09 0.34±0.10 0.26±0.10 |
Annotate: each group treatment front and back is * P＜0.05**P＜0.01 relatively
Two groups of differences compare P △＜0.05 △ △ P＜0.01
The flat oral liquid for relaxation of table 7 is to the hemorheological influence of patients with hypertension (X ± S)
| Project | Flat oral liquid for relaxation group (n=30) | Herba Apocyni veneti (Folium Apocyni Veneti) Tabellae group (n=30) | ||||
| Before controlling | After controlling | Difference | Before controlling | After controlling | Difference | |
| RBV(mpd.s) RPV(mpd.s) HCT K Fb(g/L) | 5.36±0.27 1.86±0.14 0.49±0.12 87.25±28.17 5.13±1.25 | 4.27±0.71** 1.78±0.14* 0.42±0.11* 69.45±22.31** 3.36±1.02** | 0.64±0.10△△ 0.08±0.01 0.07±0.01△△ 17.80±7.20△△ 1.77±0.85△△ | 5.11±0.69 1.90±0.15 0.50±0.13 90.03±27.44 5.10±1.30 | 4.66±0.62* 1.81±0.12 0.46±0.12 78.11±23.06 4.52±1.18 | 0.45±0.08 0.09±0.03 0.04±0.02 11.92±5.12 0.58±0.22 |
Annotate: each group treatment front and back is * P＜0.05**P＜0.01 relatively
Two groups of differences compare P △＜0.05 △ △ P＜0.01
Claims (5)
1, the health food of a kind of balancing blood pressure, adjusting blood fat is characterized in that it being the health food of being eaten plant material by the medicine-food two-purpose of following weight proportion
Parasitic loranthus 18-36 part black soybean 46-68 part red date 18-29 part
Preparation technology's method is, it is characterized in that getting parasitic loranthus, black soya bean, red date 3 flavors add 8 times, 6 times, 6 times of distilled water, flood for the first time 60min, decoct 3 times, each 60min, filtrate successively, filter, it is 1.6g/ml that filtrate is concentrated into crude drug concentration, successively adds the ZTC-III natural clarifying agent 2A6B component for preparing and fully stirs 60 ℃-80 ℃, insulation 60min, with 16000r/min centrifugation clear liquid, adjusting soup then, to be concentrated into crude drug concentration be 1.8g/ml with tube centrifuge, adds 1% Sodium Benzoate, the dissolving back is by 0.15 μ m aperture mesopore fiber device micro-filtration, the aseptic subpackaged embedding of filtrate.
2, according to the health food of the described balancing blood pressure of claim 1, adjusting blood fat, the weight proportion of raw material wherein is
Parasitic loranthus 26-32 black soybean 48-56 part red date 18-22 part.
3, the health food that refers to according to the described balancing blood pressure of claim 1, adjusting blood, wherein the weight proportion of each raw material is
18 parts of 51 portions of red dates of 29 portions of black soybean of parasitic loranthus.
4, the health food of balancing blood pressure according to claim 1, adjusting blood fat is characterized in that this health food is an oral solutions.
5, balancing blood pressure according to claim 4, preparation technology's method of regulating the health food of blood fat is, it is characterized in that getting parasitic loranthus, black soya bean, red date 3 flavors add 8 times, 6 times, 6 times of distilled water, flood for the first time 60min, decoct 3 times, each 60min, filtrate successively, filter, it is 1.6g/ml that filtrate is concentrated into crude drug concentration, successively adding the ZTC-III natural clarifying agent 2A6B component for preparing fully stirs, 60 ℃-80 ℃, insulation 60min, with 16000r/min centrifugation clear liquid, adjusting soup then, to be concentrated into crude drug concentration be 1.8g/ml with tube centrifuge, adds 1% Sodium Benzoate, the dissolving back is by 0.15 μ m aperture mesopore fiber device micro-filtration, the aseptic subpackaged embedding of filtrate.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB02125883XA CN1199584C (en) | 2002-08-01 | 2002-08-01 | Healthy food for balancing blood pressure and regulating blood fat and preparing method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB02125883XA CN1199584C (en) | 2002-08-01 | 2002-08-01 | Healthy food for balancing blood pressure and regulating blood fat and preparing method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1471846A CN1471846A (en) | 2004-02-04 |
| CN1199584C true CN1199584C (en) | 2005-05-04 |
Family
ID=34143124
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB02125883XA Expired - Fee Related CN1199584C (en) | 2002-08-01 | 2002-08-01 | Healthy food for balancing blood pressure and regulating blood fat and preparing method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1199584C (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006065608A2 (en) * | 2004-12-17 | 2006-06-22 | Bionovo, Inc. | Estrogenic extracts of morus alba and uses thereof |
-
2002
- 2002-08-01 CN CNB02125883XA patent/CN1199584C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1471846A (en) | 2004-02-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102178314B (en) | Bitter buckwheat health care beverage with auxiliary function for lowering blood pressure and production process thereof | |
| CN102940251B (en) | Health-care food for reducing blood sugar and blood fat | |
| CN102634441B (en) | A kind of preparation method of health-care vinegar | |
| KR100529793B1 (en) | The extract of pine needle and the use thereof | |
| JP4921681B2 (en) | Preventive drugs | |
| CN1107359A (en) | Galenic composition | |
| CN1199584C (en) | Healthy food for balancing blood pressure and regulating blood fat and preparing method thereof | |
| CN101879272B (en) | Chinese medicinal compound for treating coronary heart diseases, preparation method and application thereof | |
| CN1534010B (en) | Water soluble extract of red sage root and its preparation method and use | |
| CN103977390B (en) | A kind of preparation method and its usage of ginger onion medicated wine composition | |
| CN100377731C (en) | Chinese traditional medicine and its preparation method and use | |
| CN108186801A (en) | A kind of lentinan health care oral liquid and preparation method thereof | |
| KR100595459B1 (en) | Composition for inhibiting obesity | |
| CN101914164B (en) | Application of polysaccharide from mulberry leaves in preventing and treating diabetes | |
| CN1087272A (en) | A kind of Chinese powder medicine capsule that is used for the treatment of chronic ischemic heart disease | |
| Okwuonu et al. | Case Report the Potential Anti Hypertensive effects of the African Oil-bean Seed-Pentaclethra Macrophylla Bentham | |
| CN108686126A (en) | A kind of liver-protecting and alcoholism-relieving prescription and preparation and application | |
| CN101113391B (en) | Grape scorpion ant health care wine | |
| CN103055011A (en) | G6 lectin extracted from traditional Chinese medicines and applications thereof in detoxification, pressure stabilization, blood vessel softening and complication resistance | |
| CN114177163B (en) | Medicine for treating hypertension | |
| CN102614384B (en) | Traditional Chinese medicine composition for treatment of hypertension and method for preparing traditional Chinese medicine composition | |
| CN105535586A (en) | Blood sugar-reducing traditional Chinese medicine health-care product | |
| CN108236714B (en) | Composition for relieving physical fatigue and assisting in reducing blood fat and soft capsule thereof | |
| CN100384437C (en) | Botanical medicine for preventing and treating arteriosclerosis and regulating blood fat and its processing method | |
| CN101530425A (en) | Application of refined seal oil to preparation of medicines for treating chronic renal failure |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |